Cargando…

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases

BACKGROUND: The purpose was to compare the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil (FOLFOX) for unresectable colorectal cancer liver metastases (CRCLM). METHODS: Patients with unresectable CRCLM were r...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Ai-Wei, Guo, Jian-Hai, Gao, Song, Kou, Fu-Xin, Liu, Shao-Xing, Liu, Peng, Chen, Hui, Wang, Xiao-Dong, Xu, Hai-Feng, Cao, Guang, Zhu, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532863/
https://www.ncbi.nlm.nih.gov/pubmed/36212504
http://dx.doi.org/10.3389/fonc.2022.913017
_version_ 1784802214310576128
author Feng, Ai-Wei
Guo, Jian-Hai
Gao, Song
Kou, Fu-Xin
Liu, Shao-Xing
Liu, Peng
Chen, Hui
Wang, Xiao-Dong
Xu, Hai-Feng
Cao, Guang
Zhu, Xu
author_facet Feng, Ai-Wei
Guo, Jian-Hai
Gao, Song
Kou, Fu-Xin
Liu, Shao-Xing
Liu, Peng
Chen, Hui
Wang, Xiao-Dong
Xu, Hai-Feng
Cao, Guang
Zhu, Xu
author_sort Feng, Ai-Wei
collection PubMed
description BACKGROUND: The purpose was to compare the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil (FOLFOX) for unresectable colorectal cancer liver metastases (CRCLM). METHODS: Patients with unresectable CRCLM were randomly assigned to receive HAI of TOMOX or FOLFOX. The primary end points were progression-free survival (PFS) measured from the date of randomisation until the date of disease progression and objective response rate (ORR). The secondary end points were overall survival (OS) measured from the date of randomisation until the date of death from any cause, disease control rate (DCR), and adverse events. RESULTS: 113 patients were randomly assigned. With a median follow-up of 39.5 months, the PFS was 5.8 months [95% CI, 4.838–6.762]) and 4.6 months [95% CI, 3.419–5.781; P = 0.840], and the median OS was 17.6 months [95% CI, 13.828–21.372] and 13.1 months [95% CI, 11.215–14.985; P = 0.178] for the FOLFOX and TOMOX arm, respectively. The ORR were 26.1% vs 22.4% and DCR were 80.4% vs 71.4% in the FOLFOX and TOMOX arms. The most common severe adverse event was elevation of liver enzymes and pain, which did not differ in the two arms. CONCLUSION: HAI chemotherapy was effective for unresectable CRCLM. HAI of FOLFOX has similar efficacy to TOMOX, and HAI of TOMOX had shorter arterial infusion time. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT02557490.
format Online
Article
Text
id pubmed-9532863
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95328632022-10-06 A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases Feng, Ai-Wei Guo, Jian-Hai Gao, Song Kou, Fu-Xin Liu, Shao-Xing Liu, Peng Chen, Hui Wang, Xiao-Dong Xu, Hai-Feng Cao, Guang Zhu, Xu Front Oncol Oncology BACKGROUND: The purpose was to compare the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed (TOMOX) to those of oxaliplatin plus 5-fluorouracil (FOLFOX) for unresectable colorectal cancer liver metastases (CRCLM). METHODS: Patients with unresectable CRCLM were randomly assigned to receive HAI of TOMOX or FOLFOX. The primary end points were progression-free survival (PFS) measured from the date of randomisation until the date of disease progression and objective response rate (ORR). The secondary end points were overall survival (OS) measured from the date of randomisation until the date of death from any cause, disease control rate (DCR), and adverse events. RESULTS: 113 patients were randomly assigned. With a median follow-up of 39.5 months, the PFS was 5.8 months [95% CI, 4.838–6.762]) and 4.6 months [95% CI, 3.419–5.781; P = 0.840], and the median OS was 17.6 months [95% CI, 13.828–21.372] and 13.1 months [95% CI, 11.215–14.985; P = 0.178] for the FOLFOX and TOMOX arm, respectively. The ORR were 26.1% vs 22.4% and DCR were 80.4% vs 71.4% in the FOLFOX and TOMOX arms. The most common severe adverse event was elevation of liver enzymes and pain, which did not differ in the two arms. CONCLUSION: HAI chemotherapy was effective for unresectable CRCLM. HAI of FOLFOX has similar efficacy to TOMOX, and HAI of TOMOX had shorter arterial infusion time. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT02557490. Frontiers Media S.A. 2022-09-21 /pmc/articles/PMC9532863/ /pubmed/36212504 http://dx.doi.org/10.3389/fonc.2022.913017 Text en Copyright © 2022 Feng, Guo, Gao, Kou, Liu, Liu, Chen, Wang, Xu, Cao and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Feng, Ai-Wei
Guo, Jian-Hai
Gao, Song
Kou, Fu-Xin
Liu, Shao-Xing
Liu, Peng
Chen, Hui
Wang, Xiao-Dong
Xu, Hai-Feng
Cao, Guang
Zhu, Xu
A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title_full A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title_fullStr A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title_full_unstemmed A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title_short A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
title_sort randomized phase ii trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532863/
https://www.ncbi.nlm.nih.gov/pubmed/36212504
http://dx.doi.org/10.3389/fonc.2022.913017
work_keys_str_mv AT fengaiwei arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT guojianhai arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT gaosong arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT koufuxin arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT liushaoxing arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT liupeng arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT chenhui arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT wangxiaodong arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT xuhaifeng arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT caoguang arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT zhuxu arandomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT fengaiwei randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT guojianhai randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT gaosong randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT koufuxin randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT liushaoxing randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT liupeng randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT chenhui randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT wangxiaodong randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT xuhaifeng randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT caoguang randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases
AT zhuxu randomizedphaseiitrialofhepaticarterialinfusionofoxaliplatinplusraltitrexedversusoxaliplatinplus5fluorouracilforunresectablecolorectalcancerlivermetastases